PHP
IMVT icon

Parkman Healthcare Partners’s Immunovant IMVT Stock Holding History

Parkman Healthcare Partners’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-216,868
Closed -$4.11M – 106
2023
Q2 		$4.11M Buy
216,868
+30,823
+17% +$575K 0.71% 43
2023
Q1 		$2.89M Buy
186,045
+28,039
+18% +$487K 0.63% 49
2022
Q4 		$2.8M Buy
+158,006
New +$1.99M 0.75% 48
2021
Q1 		– Sell
-60,781
Closed -$2.81M – 91
2020
Q4 		$2.81M Sell
60,781
-89,370
-60% -$4.13M 0.72% 52
2020
Q3 		$5.28M Buy
150,151
+25,026
+20% +$753K 1.4% 30
2020
Q2 		$3.05M Buy
125,125
+85,000
+212% +$1.82M 0.86% 42
2020
Q1 		$625K Buy
+40,125
New +$604K 0.29% 62

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Parkman Healthcare Partners's IMVT Position: Q3 2023 in Review

Parkman Healthcare Partners sold out of Immunovant (IMVT) in Q3 2023, closing a stake of 216,868 shares — an estimated $4.11M sold.

Parkman Healthcare Partners first reported a position in IMVT in Q1 2020 and held it in 7 quarters. The position peaked at $5.28M in Q3 2020. 181 funds tracked by Wall St. Rank hold IMVT as of Q3 2023.

  • Parkman Healthcare Partners reported no remaining Immunovant position as of Q3 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 216,868 Immunovant shares in Q3 2023, an estimated $4.11M.
  • Parkman Healthcare Partners first reported a position in Immunovant in Q1 2020 and held it in 7 quarters.
  • Parkman Healthcare Partners's Immunovant position peaked at $5.28M in Q3 2020.
  • 181 funds tracked by Wall St. Rank held Immunovant as of Q3 2023.

Based on Parkman Healthcare Partners's 13F filing for Q3 2023, filed 14 Nov 2023.